AVROBIO, Inc. (AVRO)

1.1850 -0.0050 (-0.42%) At close: 04:00PM EDT

AVROBIO, Inc.

100 Technology Square
Sixth Floor
Cambridge, MA 02139
United States
(617) 914-8420
https://www.avrobio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Erik John Ostrowski M.B.A.	President, Interim CEO, CFO & Treasurer	1.25M	N/A	1972
Dr. Azadeh Golipour Ph.D.	Chief Technology Officer	1.01M	N/A	1980
Dr. Essra Ridha FFPM, M.D.	Chief Medical Officer	1.12M	N/A	1983
Mr. Jeffrey Medin Ph.D.	Scientific Founder	N/A	N/A	N/A
Mr. Steven N. Avruch J.D.	Chief Legal Officer & Secretary	506.68k	N/A	1962
Mr. Scott Gottesman	Vice President of Human Resource	N/A	N/A	N/A
Ms. Kirsten Dupuis	Chief of Staff	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate governance

AVROBIO, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.